Imeik Technology Development Co

Imeik Technology Development Co Cash Flow per Share

The Operating Cash Flow per Share of Imeik Technology Development Co (300896.SZ) as of Nov 11, 2026 is 4.60 CNY. In the previous year, Operating Cash Flow per Share was 6.42 CNY — a change of -28.29% (lower).

Cash Flow per Share

4.60CNY

YoY

-28.29%

Last updated:

Operating Cash Flow per Share of Imeik Technology Development Co is 2025 4.60 CNY. Operating Cash Flow per Share of Imeik Technology Development Co was 2024 6.42 CNY. It decreases by -28.29% lower compared to the previous year.

The Imeik Technology Development Co Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
0.45 CNY
Jan 1, 2019
1.35 CNY
Jan 1, 2020
1.43 CNY
Jan 1, 2021
3.11 CNY
Jan 1, 2022
3.94 CNY
Jan 1, 2023
6.50 CNY
Jan 1, 2024
6.42 CNY
Jan 1, 2025
4.60 CNY
The Imeik Technology Development Co Cash Flow per Share history
YEARCash Flow per ShareYoY
4.60CNY-28.29%
6.42CNY-1.28%
6.50CNY+64.82%
3.94CNY+26.82%
3.11CNY+116.67%
1.43CNY+5.92%
1.35CNY+201.36%
0.45CNY+61.00%
0.28CNY+53.02%
0.18CNY+13.76%
0.16CNY+72.97%
0.09CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co., Ltd. generates revenue through the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. The company focuses on products like injection-type sodium hyaluronate series and polydioxanone facial implants, which are used for facial and neck skin repair in medical cosmetology, surgical repair, and metabolic disease treatment. Its self-developed products target the Chinese market, where it has established a technology transformation platform for materials such as medical chitosan and polylactic acid. The firm leverages its industrialized product lines to serve medical and cosmetic applications. The company's primary customers are healthcare providers and medical facilities in China that utilize its products for skin repair, surgical procedures, and metabolic disease management. Its product portfolio includes sodium hyaluronate series for injections, polydioxanone facial implants, and other biomedical materials like medical chitosan and polylactic acid. These products are sold under the company's own brand, with no external brands mentioned in the description. Imeik's business model centers on the industrialization of its self-developed biomedical materials, transforming research into commercial products for medical and cosmetic use. The firm's focus on recombinant proteins and peptides drives its product development, targeting applications in medical cosmetology and surgical repair. It operates within the Chinese market, where it has established a technology platform for product transformation and commercialization. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Operating Cash Flow per Share of Imeik Technology Development Co is 4.60 CNY in 2025.

Operating Cash Flow per Share of Imeik Technology Development Co changed from 6.42 CNY to 4.60 CNY, representing a -28.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Imeik Technology Development Co

All Key Metrics — Imeik Technology Development Co